New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
08:49 EDTHPTXHyperion Therapeutics completes acquisition of Andromeda Biotech
Hyperion Therapeutics announced that it has completed its previously announced acquisition of Andromeda Biotech. The acquisition broadens Hyperion's pipeline to include DiaPep277, a potentially first-in-class immunotherapy for new onset Type 1 diabetes that is currently being evaluated in a fully enrolled confirmatory Phase 3 clinical study in adult patients, with results anticipated in the first quarter of 2015. DiaPep277 holds Orphan Drug designation in the U.S.
News For HPTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for HPTX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use